PubMed Health⌕ Search

Biomedical subjects

P Lanzara

Publications and source records attributed to P Lanzara.

11 recordsLinked to original sources
PubMed1998

[Subtotal thyroidectomy or total thyroidectomy in the treatment of benign thyroid disease. Our experience].

During the period January 1989-December 1994, of 322 thyroid operations, 309 were benign. The pathologic changes in the excised thyroids were 18 benign adenoma, 291 goiter 9 of which with thyroiditis. 25 patients had undergone previous partial thyroidectomy. Total thyroidectomy was performed in 224 patients. There were no operative deaths. 77 (34.3%) patients developed postoperative hypocalcemia, 10 (2.7%) transient hypoparathyroidism, 4 (1.8%) permanent hypoparathyroidism, 3 (1.3%) transient recurrent laryngeal nerve palsies, 2 (0.9%) permanent nerve damages. In our experience total thyroidectomy is the gold standard for diffuse diseases of the thyroid, because, without more specific complication than subtotal thyroidectomy, it ensures: no recurrences, an easy control of postoperative hypothyroidism, the removal of microscopic malignant foci, the stopping of ophthalmopathy evolution.

Adenoma↗
PubMed1979

Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly.

In 11 untreated acromegalic patients the plasma GH levels were determined after the acute administration of bromocriptine, haloperidol, pimozide (only in 8 patients) and of placebo. A 50% or more suppression of the basal GH levels was arbitrarily defined as a positive response to bromocriptine. Five patients displayed a negative response to bromocriptine. Of these, 4 responded to both antidopaminergic drugs. We conclude that the acute administration of antidopaminergic drugs reduces the GH secretion in some bromocriptine-insensitive acromegalic patients. Therapeutical implications will require further studies.

Acromegaly↗
PubMed1976

[Changes in blood sugar, and insulin levels induced by somatostatin in normal, diabetic and acromegalic subjects].

The effect of somatostatin on plasma sugar and insulin levels was determined in 8 normal, 7 diabetic and 5 acromegalic subjects. An absolute fall in blood sugar values on the order of about 20% was noted, though during administration of the drug only, in all cases. Normal and diabetic subjects also showed an approximately 40% decrease in blood insulin, whereas no such fall was observed in the acromegalic. In spite of the simultaneous fall in insulin levels, it was clear that the reduction in blood sugar was ascribable to a drug-induced block of glucagon secretion. The part possibly played by somatostatin in the regulation of glucide homeostasis is examined in the light of these results.

Acromegaly↗
PubMedDate not supplied

[Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].

The plasma GH response to the L-dopa test (500 mg per os) has been assessed in 7 acromegalics who had never been treated before. Whereas three patients showed an increase in plasma GH, the other four presented a paradoxical response with a significant reduction in plasma GH levels. All subjects were put on to treatment with bromocryptin (10 mg/die). Three months later it was noted that only the four subjects with paradoxical response to L-dopa responded positively to bromocryptin treatment (at least 50% reduction in plasma GH). The L-dopa test was repeated in these four patients. In three of them who presented basal levels of GH lower than 10 ng/ml the L-dopa response curve was found to be reversed. It is concluded that in responsive patients, bromocryptin not only reduces GH levels but also normalizes the response to certain stimuli such as L-dopa.

Acromegaly↗